Showing 1541-1550 of 1644 results for "".
- High-Frequency Spinal Cord Stimulation Included in Endocrinology Guideline for Painful Diabetic Neuropathy Treatmenthttps://practicalneurology.com/news/high-frequency-spinal-cord-stimulation-included-in-endocrinology-guideline-for-painful-diabetic-neuropathy-treatment/2470037/High-frequency (10 kHz) spinal cord stimulation (HF-SCS) is now included in the Diabetes Clinical Practice Guideline for painful diabetic neuropathy (PDN) treatment by The Association of Clinical Endocrinology (AACE). Inclusion of HF-SCS was based on the results from the SENZA-PDN trial (
- FDA Approves Expanded Indication for Use of Stiripentol for Dravet Syndrome in Children Age 6 Months or Morehttps://practicalneurology.com/news/fda-approves-expanded-indication-for-use-of-stiripentol-for-dravet-syndrome-in-children-age-6-months-or-more/2470029/The Food and Drug Administration (FDA) has approved stiripentol (Diacomit; Biocodex, San Mateo, CA) for the treatment of seizures associated with Dravet Syndrome in patients 6 months of age and older, weighing 15 lbs or more and taking clobazam. In 2 clinical studies, the drug
- Pediatric Migraine Frequency Increased During COVID-19 Pandemichttps://practicalneurology.com/news/pediatric-migraine-frequency-increased-during-covid-19-pandemic/2469996/Data published in the Journal of Child Neurology suggest that elevation of stress associated with disruptions to daily life, social distancing practices, and COVID-19 anxiety greatly affected children with headache disorders. A new study of children with headache showed that headache fre
- Experiencing Racism Negatively Affects Cognitive Healthhttps://practicalneurology.com/news/experiencing-racisms-negatively-affects-cognitive-health/2469987/Higher exposure to racism among marginalized groups may be a substantial driver of racial/ethnic disparities in cognitive health. In a study of 942 community-dwelling adults, mean age 55±11, structural racism was associated with lower episodic memory. Experiences of both interpersonal and
- Socioeconomic Status Affects Cognition and Dementiahttps://practicalneurology.com/news/effects-of-socioeconomic-status-on-cognition-and-dementia-1/2469985/At the Alzheimer Association International Conference 2022 (AAIC2022) in San Diego, CA and online, multiple studies showing the impact socioeconomic status and other social determinants of health on cognitive health, dementia, and Alzheimer disease were presented. Perceived n
- Intensive Care Unit Stays Doubles Risk of Dementiahttps://practicalneurology.com/news/having-a-stay-in-an-intensive-care-unit-correlated-with-doubled-incidence-of-dementia/2469976/In a study presented at the Alzheimer's Association International Congress 2022 (AAIC2022), a correlation was found between stays in intensive care units (ICUs) and dementia. After adjusting for age, sex, education, and racialized identity, individuals who had a stay in t
- Herpes Zoster May Reduce Dementia Riskhttps://practicalneurology.com/news/herpes-zoster-may-reduce-dementia-risk/2469928/Despite scientific speculation that inflammation may increase risk of dementia, a new study published in Neurology has found that herpes zoster is not associated with an increased risk of dementia. “As a person’s age increases, so does their risk of dementia,
- Lecanemab for Potential Treatment of Early Alzheimer’s Disease Fully Submitted to FDAhttps://practicalneurology.com/news/lecanemab-for-potential-treatment-of-early-alzheimers-disease-fully-submitted-to-fda/2469907/A rolling submission to the Food and Drug Administration (FDA) for approval lecanemab (BAN2401; Eisai, Tokyo, Japan) for treatment of mild cognitive impairment associated with Alzheimer disease (AD) or mild AD has been completed. Submission for approval via the accelerated pathway
- Cerebrospinal Fluid Diagnostic Test for Synucleinopathies Now Availablehttps://practicalneurology.com/news/cerebrospinal-fluid-diagnostic-test-for-synucleinopathies-now-available/2469865/A new, first-in-class laboratory test (Syntap; Amprion, San Diego, CA) has become available that provides accurate measurement of misfolded α-synuclein aggregates in cerebrospinal fluid (CSF). The test is certified by Clinical Laboratory and Improvement Amendments (CLIA) and Clinical Associ
- FDA Approves Ganaxolone for Treatment CDKL5 Deficiency Disorder, a Rare Genetic Epilepsyhttps://practicalneurology.com/news/fda-approves-ganaxolone-for-treatment-cdkl5-deficiency-disorder-a-rare-genetic-epilepsy/2469857/The Food and Drug Administration (FDA) has approved ganaxolone (Ztalmy; Marinus Pharmaceuticals, Radnor, PA) for treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency, a rare genetic epilepsy. Ganaxolone is an oral suspension and was approved for individuals, age